DR. BARRY I. BOCKOW, M.D.
Medical Practice at 43 St, Seattle, WA

5912006, Jun 15, 1999

Aug 28, 1996

8/704819

Barry I. Bockow - Seattle WA
Marc D. Erlitz - Kirkland WA

EBOC, Inc. - Seattle WA

A61F 1302

424431

There is disclosed a composition and method for reducing or alleviating the discomforting symptoms associate with menstruation, particularly menstrual pain. The composition is administered by topical or local administration to the uterus or vaginal tissues of a women in need thereof, and contains an omega fatty acid in combination with a cyclo-oxygenase inhibitor. Preferred omega fatty acids include docosahexaenoic acid and eicosapentaenoic acid, and preferred cyclo-oxygenase inhibitors include, ibuprophen, acetylsalicylic acid and salicylic acid. The composition may further include pharmaceutically acceptable carriers or diluents, and may be locally applied via intracervical or intrauterine application, or may be topically applied to the skin of the lower abdomen.

5409955, Apr 25, 1995

May 13, 1993

8/062459

Barry I. Bockow - Seattle WA
Marc D. Erlitz - Kirkland WA

A61K 31235, A61K 31225, A61K 3120, A61K 3119

514560

There is disclosed a composition for inhibiting uterine contractility by topical or local administration. The composition contains an omega fatty acid in combination with a cyclo-oxygenase inhibitor. Preferred omega fatty acids include docosahexaenoic acid and eicosapentaenoic acid, and preferred cyclo-oxygenase inhibitors include acetylsalicylic acid and salicylic acid. The composition may further include pharmaceutically acceptable carriers or diluents, and may be locally applied via intracervical or intrauterine application, or may be topically applied to the skin of the lower abdomen.

5411988, May 2, 1995

Oct 27, 1993

8/144054

Barry I. Bockow - Seattle WA
Marc D. Erlitz - Kirkland WA

A61K 3120, A61K 3161, A61K 3107

514560

There is disclosed compositions and methods for inhibiting inflammation and/or adhesion formation in a patient. The compositions comprise omega-3 and/or omega-6 fatty acids, a nonionic surfactant, and a pharmaceutically acceptable carriers or diluents. The omega fatty acid compositions may optionally contain cyclooxygenase inhibitors and other additives and preservatives such as dextrose and vitamin A. The methods of inhibiting inflammation and/or adhesion formation in a patient comprise administration of an effective quantity of a composition to a body cavity of the patient.

5709855, Jan 20, 1998

Sep 22, 1995

8/538992

Barry I. Bockow - Seattle WA

A61K 3580, A61K 3120, A61K 3160, A61K 3119

424 937

A composition for preventing or treating inflammation and/or pain by topical administration are disclosed. The composition contains an omega fatty acid in combination with spirulina. Preferably, the omega fatty acid is a mixture of omega-3 fatty acids and omega-6 fatty acids. Omega-3 fatty acids include eicosapentaenoic acid and docosahexanoic acid, and omega-6 fatty acids include gamma-linolenic acid and dihomo-gamma-linolenic acid. The composition may further include pharmaceutically acceptable carriers or diluents, vitamins A and E, and a cyclooxygenase inhibitor such as methyl salicylate.

6201022, Mar 13, 2001

Mar 27, 1997

8/824931

Philip J. Mease - Seattle WA
Barry I. Bockow - Seattle WA
Marc D. Erlitz - Kirkland WA

MyoRx, Inc. - Seattle WA

A61K 3120, A61K 3160, A61K 3161

514560

Methods are disclosed for treating neurotransmitter-mediated pain syndromes such as fibromyalgia. Such methods include topically administering an effective amount of a composition containing an omega fatty acid in combination with a carrier or diluent. The composition may also contain a cyclo-oxygenase inhibitor and other optional components, such as vitamins A, E and/or C.

5650157, Jul 22, 1997

Mar 22, 1994

8/247682

Barry I. Bockow - Seattle WA

A61K 600

424401

Some otherwise desirable oil compositions derived from natural sources are characterized by an unpleasant odor. Fractions or combinations of such oils may also be so characterized. Stable, deodorized oils may be prepared by adding an amount of a deodorizing agent effective to substantially reduce the odor of the derived oil composition, fraction or combination thereof to that oil composition, fraction or combination. The pharmaceutical topical compositions of the present invention contain these stable, deodorized oil compositions and exhibit enhanced penetration properties and achieve enhanced patient response. The improved pharmaceutical compositions of the present invention may be used to manage pain and/or to treat the underlying ailments. Methods of making such topical pharmaceutical compositions are also discussed.

2002005, May 9, 2002

Mar 21, 2001

09/814394

Barry Bockow - Seattle WA, US
Marc Erlitz - Kirkland WA, US
Philip Mease - Seattle WA, US

A61K031/202

514/560000

There is disclosed compositions and methods for treating or preventing cardiovascular conditions by intravascular administration of an omega fatty acid to a patient in need thereof. The omega fatty acid is intravascularly administered preferably in close proximity to the treatment site. Cardiovascular conditions which may be treated or prevented according to this invention include coronary artery disease, myocardial infarction, cerebrovascular disease, stroke, peripheral vascular disease, and atherosclerosis or thrombosis of arteries or veins supplying any organ system. Thrombosis or restenosis occurring in grafts, stents, and in areas of diagnostic or therapeutic intervention such as angioplasty or diagnostic radiology sites can also be treated or prevented.